ATE403745T1 - Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis - Google Patents

Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Info

Publication number
ATE403745T1
ATE403745T1 AT99972008T AT99972008T ATE403745T1 AT E403745 T1 ATE403745 T1 AT E403745T1 AT 99972008 T AT99972008 T AT 99972008T AT 99972008 T AT99972008 T AT 99972008T AT E403745 T1 ATE403745 T1 AT E403745T1
Authority
AT
Austria
Prior art keywords
sepsis
drugs
development
determining susceptibility
treating
Prior art date
Application number
AT99972008T
Other languages
English (en)
Inventor
Giovine Francesco Di
Gordon Duff
Original Assignee
Interleukin Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Interleukin Genetics Inc filed Critical Interleukin Genetics Inc
Application granted granted Critical
Publication of ATE403745T1 publication Critical patent/ATE403745T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/131—Allele specific probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99972008T 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis ATE403745T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/183,850 US6251598B1 (en) 1998-10-30 1998-10-30 Methods for diagnosing sepsis

Publications (1)

Publication Number Publication Date
ATE403745T1 true ATE403745T1 (de) 2008-08-15

Family

ID=22674558

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99972008T ATE403745T1 (de) 1998-10-30 1999-11-01 Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis

Country Status (10)

Country Link
US (2) US6251598B1 (de)
EP (1) EP1127168B1 (de)
JP (1) JP2002533096A (de)
AT (1) ATE403745T1 (de)
AU (1) AU779772B2 (de)
CA (1) CA2346960A1 (de)
DE (1) DE69939269D1 (de)
ES (1) ES2308861T3 (de)
IL (1) IL142438A0 (de)
WO (1) WO2000037679A2 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711040D0 (en) * 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
US20050032077A1 (en) * 1998-03-10 2005-02-10 Duff Gordon W. Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis
WO2002024951A1 (en) * 2000-09-20 2002-03-28 Genaissance Pharmaceuticals, Inc. Haplotypes of the il1b gene
US20040028651A1 (en) * 2001-03-29 2004-02-12 Karrupiah Muthumani Composition and methods of using hiv vpr
JP2005523879A (ja) * 2001-10-05 2005-08-11 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア Ｓｉｒｓ／ｓｅｐｓｉｓを治療及び予防するための組成物及び方法
US20080311581A1 (en) * 2001-11-19 2008-12-18 David Wyllie Functional polymorphisms of the interleukin-1 locus affecting transcription and susceptibility to inflammatory and infectious diseases
KR101019131B1 (ko) * 2001-11-19 2011-03-07 인터레우킨 제네틱스, 인코포레이티드 염증성 질환 및 감염성 질환에 대한 감수성 및 전사에영향을 미치는 인터루킨-1 좌의 기능적 다형성
CN1829730A (zh) * 2002-11-12 2006-09-06 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
EP1565570A4 (de) * 2002-11-12 2005-12-28 Becton Dickinson Co Sepsis- oder sirs-diagnose mittels biomarkerprofilen
US20040096917A1 (en) * 2002-11-12 2004-05-20 Becton, Dickinson And Company Diagnosis of sepsis or SIRS using biomarker profiles
WO2005038427A2 (en) * 2003-06-05 2005-04-28 Medical Gene Center Ltd. Rapid identification of viruses of the upper respiratory tract infection including sars causing coronus viruses
EP1673472B1 (de) * 2003-10-06 2011-02-09 Novartis AG Verwendung genetischer polymorphismen zur vorhersage arzneistoffinduzierter hepatotoxizität
AU2005219472A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Thrombomodulin (THBD) haplotypes predict outcome of patients
AU2005219473A1 (en) * 2004-03-04 2005-09-15 The University Of British Columbia Toll-like receptor 2 (TLR-2) haplotypes predict outcome of patients
US8034553B2 (en) * 2004-06-24 2011-10-11 Kimberly-Clark Worldwide, Inc. Biomarkers for wound healing
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
EP2361933A3 (de) 2005-01-26 2012-05-02 Amgen Fremont Inc. Antikörper gegen Interleukin-1 Beta
RU2286154C2 (ru) * 2005-02-17 2006-10-27 Владимир Алексеевич Шатров Способ лечения воспалительных заболеваний головного мозга
JP4562768B2 (ja) 2005-03-30 2010-10-13 株式会社島津製作所 反応容器における不揮発性液体分注方法及び反応容器処理装置
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
WO2009123737A2 (en) 2008-04-03 2009-10-08 Becton, Dickinson And Company Advanced detection of sepsis
US20120087870A1 (en) * 2008-12-19 2012-04-12 Hentges Francois Novel caviidae allergens and uses thereof
JP2014506889A (ja) 2011-02-18 2014-03-20 ステムディーアール インク． Ｓｉｒｔ１発現誘導物質を含む敗血症または敗血症性ショックの予防または治療用組成物
US10126305B2 (en) 2013-06-25 2018-11-13 University of Pittsburg—Of the Commonwealth System of Higher Education Proteomic biomarkers of sepsis in elderly patients
WO2017123696A1 (en) 2016-01-12 2017-07-20 Interleukin Genetics, Inc. Methods for predicting response to treatment
US10329620B2 (en) 2017-01-12 2019-06-25 Cardioforecast Ltd. Methods and kits for treating cardiovascular disease
EP3980561A1 (de) 2019-06-06 2022-04-13 Sitokine Limited Zusammensetzungen und verfahren zur behandlung von lungen-, kolorektal- und brustkrebs
WO2021028469A1 (en) 2019-08-12 2021-02-18 Sitokine Limited Compositions and methods for treating cytokine release syndrome and neurotoxicity
WO2021205013A1 (en) 2020-04-09 2021-10-14 Sitokine Limited Compositions and methods for treating covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
JPH05506986A (ja) 1990-05-01 1993-10-14 カイロン　コーポレイション インターロイキン―１拮抗物質及びその利用
US5916891A (en) 1992-01-13 1999-06-29 Smithkline Beecham Corporation Pyrimidinyl imidazoles
WO1995001997A1 (en) 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
DE4408890A1 (de) 1994-03-16 1995-09-21 Knoll Ag Verwendung von Il-1-Antagonisten als Arzneimittel zur Behandlung von Erkrankungen mit einem erhöhten Interleukin-6 Serumspiegel
US5686246A (en) 1995-08-03 1997-11-11 Kornman; Kenneth S. Detecting genetic predisposition to periodontal disease
US5942390A (en) * 1996-01-12 1999-08-24 Cedars-Sinai Medical Center Method of diagnosing predisposition for ulcerative colitis in Jewish population by detection of interleukin-1 receptor antagonist polymorphism
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
GB9621129D0 (en) 1996-10-10 1996-11-27 Duff Gordon W Detecting genetic predisposition to sight-threatening diabetic retinopathy
US6210877B1 (en) 1997-03-10 2001-04-03 Interleukin Genetics, Inc. Prediction of coronary artery disease
GB9711040D0 (en) 1997-05-29 1997-07-23 Duff Gordon W Prediction of inflammatory disease
TR200001263T2 (tr) 1997-11-07 2000-12-21 Interleukin Genetics, Inc. Kronik tıkayıcı solunum-yolu hastalığının teşhis ve terapötikleri
US6251598B1 (en) * 1998-10-30 2001-06-26 Interleukin Genetics, Inc. Methods for diagnosing sepsis

Also Published As

Publication number Publication date
US6251598B1 (en) 2001-06-26
WO2000037679A2 (en) 2000-06-29
JP2002533096A (ja) 2002-10-08
EP1127168B1 (de) 2008-08-06
US6551785B2 (en) 2003-04-22
AU779772B2 (en) 2005-02-10
IL142438A0 (en) 2002-03-10
WO2000037679A3 (en) 2001-01-11
ES2308861T3 (es) 2008-12-01
DE69939269D1 (de) 2008-09-18
CA2346960A1 (en) 2000-06-29
EP1127168A2 (de) 2001-08-29
US20010034032A1 (en) 2001-10-25
AU3995600A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
DE69939269D1 (de) Verfahren zur bestimmung der suzeptibilität zur sepsisentwicklung und arzneimittel zur behandlung von sepsis
ATE376187T1 (de) Nachweis von erkrankungen der nieren und behandlung
DE69735295D1 (de) Verfahren zur Aufkonzentrierung von Antikörperlösungen
DE69739000D1 (de) Gerät und verfahren zur bestimmung der quelle eines lokalsignals
ATE188778T1 (de) Verfahren und verbindungen zur magnetorelaxometrischen detektion von analyten und deren verwendung
DE69430231D1 (de) Biosensor zum Messen der Alkoholkonzentration, Verfahren zur Herstellung des Biosensors, und den Biosensor benutzendes Betrunkenheitsmessgerät
DE59601159D1 (de) Verfahren zum gegenseitigen ausrichten von körpern und lagemesssonde hierfür
DE69737258D1 (de) Verfahren und Vorrichtung zur Detektion von akutem myokardischem Infarkt
DE69534399D1 (de) Verfahren und Gerät zur Bestimmung von Merkmalpunkten
DE69625777D1 (de) Verfahren zur Bestimmung der Konzentration eines magnetischen Pulvers und Vorrichtung dazu
DD138921A5 (de) Verfahren und reagens zur bestimmung von alpha-amyl&se
DE69619611D1 (de) Verfahren und Vorrichtung zur Bestimmung der petrologischen Eigenschaften von Schichtgesteinen
DE69605590D1 (de) Verfahren zum Nachweis von Protein und Kit dafür
DE69936553D1 (de) Verfahren zur Konzentrationsmessung von NOx
DE69626311D1 (de) Zusammensetzung zur behandlung von wäsche sowie verfahren hierfür
DE69124511D1 (de) Verfahren für den nachweis und/oder die bestimmung von hormonen
DE69524919D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Gaskomponenten
ATA924378A (de) Verfahren zur bestimmung von prothrombin und reagens zur durchfuehrung des verfahrens
DE69934789D1 (de) Verfahren zur bestimmung der antibiotikasensitivität von bakterien
DE59814359D1 (de) Mikrostrukturierter biosensor, verwendung des biosensors und verfahren zur immobilisierung von biokatalysatoren
ATE506075T1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE69422890D1 (de) Verfahren und Vorrichtung zur Bestimmung der Konzentration von Verunreinigungselementen
NO973823L (no) Påvisning av antistoffproduksjon
DE69611713D1 (de) Verfahren zur Bestimmung des spezifischen Gewichts von Flüssigkeiten
DE69838872D1 (de) Verfahren und testkit zum nachweis von heroin

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties